CA3217649A1 - Vecteurs aavrh74 de therapie genique de dystrophies musculaires - Google Patents

Vecteurs aavrh74 de therapie genique de dystrophies musculaires Download PDF

Info

Publication number
CA3217649A1
CA3217649A1 CA3217649A CA3217649A CA3217649A1 CA 3217649 A1 CA3217649 A1 CA 3217649A1 CA 3217649 A CA3217649 A CA 3217649A CA 3217649 A CA3217649 A CA 3217649A CA 3217649 A1 CA3217649 A1 CA 3217649A1
Authority
CA
Canada
Prior art keywords
sequence
aavrh74
itr
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3217649A
Other languages
English (en)
Inventor
Arun Srivastava
Keyun Qing
Barry John Byrne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of CA3217649A1 publication Critical patent/CA3217649A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

L'invention concerne des protéines de capside de VAA modifiées, des particules, des vecteurs d'acide nucléique et leurs compositions, ainsi que leurs méthodes d'utilisation.
CA3217649A 2021-04-23 2022-04-22 Vecteurs aavrh74 de therapie genique de dystrophies musculaires Pending CA3217649A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163179097P 2021-04-23 2021-04-23
US63/179,097 2021-04-23
US202263327410P 2022-04-05 2022-04-05
US63/327,410 2022-04-05
PCT/US2022/025916 WO2022226289A2 (fr) 2021-04-23 2022-04-22 Vecteurs aavrh74 de thérapie génique de dystrophies musculaires

Publications (1)

Publication Number Publication Date
CA3217649A1 true CA3217649A1 (fr) 2022-10-27

Family

ID=81648417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3217649A Pending CA3217649A1 (fr) 2021-04-23 2022-04-22 Vecteurs aavrh74 de therapie genique de dystrophies musculaires

Country Status (11)

Country Link
US (1) US20220347317A1 (fr)
EP (1) EP4326857A2 (fr)
JP (1) JP2024514962A (fr)
KR (1) KR20240000542A (fr)
AU (1) AU2022262407A1 (fr)
BR (1) BR112023021495A2 (fr)
CA (1) CA3217649A1 (fr)
CO (1) CO2023015911A2 (fr)
IL (1) IL307881A (fr)
TW (1) TW202304954A (fr)
WO (1) WO2022226289A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2839014B1 (fr) * 2012-04-18 2020-12-16 The Children's Hospital of Philadelphia Composition et procédés pour un transfert génique hautement efficace à l'aide de variants de capside aav
EP3221456B1 (fr) 2014-11-21 2021-09-22 University of Florida Research Foundation, Inc. Vecteurs viraux adéno-associés recombinés au génome modifié

Also Published As

Publication number Publication date
EP4326857A2 (fr) 2024-02-28
AU2022262407A1 (en) 2023-10-26
US20220347317A1 (en) 2022-11-03
AU2022262407A9 (en) 2023-11-09
IL307881A (en) 2023-12-01
WO2022226289A3 (fr) 2023-03-02
KR20240000542A (ko) 2024-01-02
JP2024514962A (ja) 2024-04-03
CO2023015911A2 (es) 2023-11-30
BR112023021495A2 (pt) 2023-12-19
TW202304954A (zh) 2023-02-01
WO2022226289A2 (fr) 2022-10-27

Similar Documents

Publication Publication Date Title
US11325956B2 (en) Dual-AAV vector-based systems and methods for delivering oversized genes to mammalian cells
JP7452953B2 (ja) １色覚および他の疾患の治療のためのプロモーター、発現カセット、ベクター、キット、ならびに方法
US11266748B2 (en) Recombinant adeno-associated virus vectors to target medullary thyroid carcinoma
JP5922095B2 (ja) 薬理学的に誘導される導入遺伝子アブレーション系
EP2761009B1 (fr) Système d'ablation de transgène médié par un vecteur viral adéno-associé inductible
JP2023503637A (ja) マイクロジストロフィン遺伝子治療コンストラクト及びその使用
EP3221456A2 (fr) Vecteurs viraux adéno-associés recombinés au génome modifié
KR20220133854A (ko) 유전적 청력 상실 치료를 위한 아데노 관련 바이러스(aav) 시스템
WO2008021140A2 (fr) Production de aav recombinant dans des cellules mammaliennes
US20020076754A1 (en) Overcoming AAV vector size limitation through viral DNA hetero-dimerization
CN116209768A (zh) 用于通过高变区交换工程化新杂合aav衣壳的方法
US20240181083A1 (en) Aavrh74 vectors for gene therapy of muscular dystrophies
US20220347317A1 (en) Aavrh74 vectors for gene therapy of muscular dystrophies
US20030190746A1 (en) Gene expression control system and its use in recombinant virus packaging cell lines
JP2023524291A (ja) 異種間適合性アデノ随伴ウイルス組成物およびその使用方法
CN117355603A (zh) 用于肌营养不良的基因治疗的aavrh74载体
US11999965B2 (en) Bocaparvovirus small noncoding RNA and uses thereof
JP2007504219A (ja) 関節リウマチのインビボ遺伝子治療のためのａａｖベクター
WO2023205610A2 (fr) Capsides aav hybrides
WO2023044438A2 (fr) Particules d'aavrh74 pour la thérapie génique d'une maladie musculaire
WO2023044441A1 (fr) Particules de vaa avec répétitions terminales inversées modifiées pour expression génique accrue dans le muscle
WO2022232029A2 (fr) Vecteurs vaa synthétiques pour l'administration répétée de gènes thérapeutiques
Ling The development of adeno-associated virus serotype 3 vector-based potential gene therapy for human liver cancer